Chiesi Farmaceutici Licenses Tum Bio’s NCE401 for $74M
Chiesi Farmaceutici Licenses Tum Bio’s NCE401 for $74M
Shots:
- Tum Bio to receive $1M upfront, up to $73M milestones and royalties on sales. Chiesi to get worldwide development and commercialization rights & will be responsible for its clinical trials
- The focus of the agreement is to develop and commercialize NCE401, a TGF-beta inhibitor in the fields of respiratory diseases
- NCE401 is a preclinical candidate used for inhibiting transforming growth factor beta (TGF-β) pathway, indicated for fibrotic diseases including pulmonary fibrosis
Click here to read full press release/ article | Ref: Business Korea | Image: The Investors